ArticleFibrogenesis & tissue repair2010
The multifaceted role of pirfenidone and its novel targets.
Article in Fibrogenesis & tissue repair, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury
Molecular and Clinical Study of the Effect of Zaxcell Versus Effezel in the Inflammatory and Scarring Process of Moderate and Severe Acne
Who cites it
69 citing papers in PubMed, 159 citations in OpenAlex.
- Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.Nature medicine · 2021Trial
- Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.Hepatology international · 2020Trial
- Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study.Journal of diabetes research · 2016Trial
- Pirfenidone gel in patients with localized scleroderma: a phase II study.Arthritis research & therapy · 2015Trial
- Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.BMC gastroenterology · 2014Trial
- Inefficacy of dexamethasone and pirfenidone as comparators in the bleomycin-induced pulmonary fibrosis model in SD rats.Frontiers in medicine · 2026Article
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.BMC gastroenterology · 2025Article
- Targeting CDK7/12/13 functional synergism reverses myofibroblast activation and ameliorates lung fibrosis.iScience · 2025Article
- Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction.Therapeutic advances in drug safety · 2024Article
- Implant-based breast surgery and capsular formation: when, how and why?-a narrative review.Annals of translational medicine · 2023Review
- Sarcoidosis-associated pulmonary fibrosis: joining the dots.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- A Soft Skin Adhesive (SSA) Patch for Extended Release of Pirfenidone in Burn Wounds.Pharmaceutics · 2023Article
- Triple-negative breast cancer cells invade adipocyte/preadipocyte-encapsulating geometrically inverted mammary organoids.Integrative biology : quantitative biosciences from nano to macro · 2023Article
- Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.The European respiratory journal · 2023Article
- Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice.Molecules (Basel, Switzerland) · 2023Article
- Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes.International journal of molecular sciences · 2023Article
- Article
- Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.Respiratory research · 2022Article
- TGF-β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation.Clinical and translational medicine · 2022Article
- The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.Therapeutic advances in musculoskeletal disease · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal models of lung, liver and renal fibrosis. These pathologies share many fibrogenic pathways with an abnormal fibrous wound-healing process; consequently, tissue repair and tissue regeneration-regulating mechanisms are altered.
objectiveTo investigate the usefulness of PFD as an antifibrotic agent in clinical and experimental models of fibrotic disease.
conclusionsThere is a growing understanding of the molecular effects of PFD on the wound healing mechanism, leading to novel approaches for the management of fibrosis in lung, liver and renal tissues. Although the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.